Hercules Capital的动态

Cardiac implant devices?is valued $30,539million in the year 2017 and is expected to grow at a CAGR of 12.5% from 2018-2023. The report incorporates in-depth assessment of the competitive landscape, product market sizing, product benchmarking, market trends, product developments, financial analysis, strategic analysis and so on to gauge the impact forces and potential opportunities of the market.Apart from this the report also includes a study of major developments in the market such as product launches, agreements, acquisitions, collaborations, mergers and so on to comprehend the prevailing market dynamics at present and its impact during the forecast period 2018-2024. ?? ?????? ???????? ?????????????????????? @ https://lnkd.in/g3nQj5mh ? ?????? ?????? ?????? ???????????? @ https://lnkd.in/gBJnvRXB ????????? ?????????????? : Medtronic, Abbott, Boston Scientific , Edwards Lifesciences , LivaNova , BIOTRONIK, St. Jude Children's Research Hospital MicroPort , Terumo Blood and Cell Technologies , Cook Medical, Cardiac Science , Sorin Group ? (???????? ?????? ???????????????? ???? ????????$ ???? ?????? ???????????? ?????????????????? | ?????? ????????: ????????????????)

Strategy and its execution. Bravo, Johnson & Johnson. Bold statement. $30 billion in planful M&A activity is nothing to sneeze at, particularly with the numbers quoted on the year-over-year performance for cardiology. This is very much a long view. And it looks like JNJ has the talent bench to actually get the job done - since “M&A is easy, but integration is hard.” Other interesting takeaways for me: ? RECORNEA’s announcement about its #keracotonus treatment ? the two gastric mentions, including the device that passes naturally after displacing stomach volume (hence food capacity) ——— Social media allows folks like Holly Scott and their thinking to be available. Sunday morning wouldn’t be Sunday morning for me without a cup of coffee and Holly’s curation. Who speaks into your professional life? Who do you seek out? I look for Kevin Berchelmann, Matthew Ray Scott, Bryan Sagray and Joe Mullings. How about you? #leadership #changinglives #dothething

CSA Medical Inc Secures $53M Series D to Advance Breakthrough Chronic Bronchitis Therapy. CSA Medical, the developer of the innovative RejuvenAir? System, has closed an oversubscribed $53 million Series D financing round, co-led by TVM Capital Life Science and Yonjin Ventures. This funding will support CSA Medical's FDA premarket approval (PMA) process and the commercial launch of RejuvenAir in the U.S. The RejuvenAir System utilizes liquid nitrogen spray cryotherapy to treat chronic bronchitis—targeting the root cause of the disease. As chronic bronchitis affects over 9 million people in the U.S. alone, CSA Medical is poised to revolutionize care for this underserved population. With strong investor backing and an experienced team, the company is well-positioned for market impact, providing a groundbreaking solution to one of the largest subsets of COPD. #MedicalDevices #Cryotherapy #ChronicBronchitis #HealthcareInnovation #COPD

Weekly Industry Life Science News! ?? ?? Gilead makes headlines by paying J&J $320M to exit a licensing deal for seladelpar, while Zimmer Biomet expands its hip portfolio with the acquisition of OrthoGrid. On the flip side, Lykos faces FDA setback with its MDMA treatment for PTSD. ?? Fascinating discoveries in the field include mini-lungs shedding light on COVID's activity and the lung's immunity, and a pepper chemical that shows promise in preventing hearing loss from powerful antibiotics. ?? Notable industry shifts include James Wilson's departure from Penn to launch two new biotechs, Exscientia merging into Recursion after a challenging year, and FDA's class 1 recall for Medtronic's nerve monitoring tech. ?? Collaboration is key as Abbott and Medtronic join forces to integrate CGM and insulin delivery systems, while Bayer partners with Alara imaging to enhance CT radiation dose monitoring. ?? Updates on innovation and leadership include Diality securing FDA clearance for its hemodialysis system, Charles River reporting a Q2 revenue dip, and Rho appointing NYU neurologist Andrew Feigin as the new CMO. ?? In other news, TPG boosts investments in life sciences to $580M, Genentech's program accelerates diverse patient enrollment, and NovAliX collaborates with Bruker to revolutionize drug discovery methods. Stay informed with the latest developments in the life science industry! #LifeScience #IndustryNews #HealthcareInnovation Connect with me for more weekly update!

The life sciences sector continues to drive innovation, with notable achievements pushing the boundaries of healthcare solutions. From regulatory breakthroughs to transformative financing rounds, these recent milestones are shaping the future of patient care and medical technology: Ultragenyx received Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta. InterVene, Inc. secured $13 million in Series A financing to advance the Recana System through US market clearance. Borvo Medical received U.S. FDA 510(k) clearance for its innovative surgical brain treatment device, offering a minimally invasive option. Arda Therapeutics closed a $43 million Series A round to advance targeted cell depletion therapies. SI-BONE completed its first-in-patient procedures using its FDA Breakthrough Device for pelvic fracture fixation. Cytovale raised $100 million in Series D funding to accelerate the commercial expansion of its rapid sepsis solution. Glooko secured $100 million in Series F financing and appointed Mike Alvarez as Chief Executive Officer. MiLaboratories raised a total of $10 million in Series A funding to revolutionize genomic research. Gritstone bio filed for bankruptcy in an effort to save its clinical research efforts. As the life sciences industry continues to evolve, these accomplishments showcase just a fraction of the transformative work taking place in biotech and healthcare. Stay tuned for more exciting updates as these innovations drive progress! #LifeScience #Biotech #HealthTech #Innovation #Healthcare #ClinicalTrials #FDAApproval #Pharma #BiotechNews #DrugDevelopment #MedTech #HealthcareInnovation #OsteogenesisImperfecta #Sepsis #SurgicalDevices #GenomicResearch #PelvicFractures #CellTherapy #SeriesA #Longevity #CEO #Bankruptcy

Protembis GmbH successfully closes €30m #SeriesB Financing Round for the initiation of PROTEMBO Investigational Device Exemption (IDE) Pivotal Trial. Aachen, Germany based Protembis have developed ProtEmbo - a catheter-based cerebral protection system to deflect embolic material away from the cerebrovascular circulation during leftsided heart procedures – in particular transcatheter aortic valve replacement (TAVR). The round was co-led by a European consortium of VC investors including Sweden-based Segulah Medical Acceleration, Italy-based XGEN Venture SGR S.p.A. and Germany-based TVF | TechVision Fonds. ?“It reflects the fact that the field of cerebral embolic protection is buoyant, and that future growth will be driven by younger and lower risk patients who have zero tolerance for brain injury risk when selecting to undergo transcatheter aortic valve replacement.” Conrad Rasmus #Cardiovascular #SeriesB #Ventures #Investment #MedTech

?? SmartCella Holding AB has completed a new share issue, raising approximately €50m ($54.17m) to expedite its growth and bolster the commercialisation of its endovascular device, the Extroducer, as well as strengthen cell and mRNA operations. They plan to use the funds for further organisational and infrastructural investments, while also ramping up commercialisation and marketing initiatives for the device. ?? SmartCella CEO Niklas Prager said: “With the new proceeds, we will continue to build our organisation and drive accelerated growth. We will have a specific focus on ramping up the commercialisation of the Extroducer, which I believe is one of the most groundbreaking innovations in targeted delivery solutions, carrying therapies directly into otherwise hard-to-reach tumours or organs." ?? Read more: https://lnkd.in/d6aJEEQv ?? Follow Guided Solutions to receive the latest #MedTech news daily and subscribe to our weekly newsletter: https://lnkd.in/d98KnNqc #MedicalDevices #MedicalDevice #MedicalEquipment #Medicine #HealthTech #Surgeons #GuidedSolutions

Market Access: What Medtech Can Learn from Pharma - Medtech companies can learn from Pharma’s evidence-based success to evolve their business strategies, expand market access and thrive. #medtech https://bit.ly/3YAZhZB

This article is a must read for #MedTech leaders looking to deepen their market access strategies. It explores how organizations can harness insights from evidence-driven, continuous engagement models to unlock new revenue while enhancing patient outcomes. We're in a true cycle of change in MedTech; companies who adapt strategies such as this will shift the competitive landscape.

????Exciting developments at California-based Pulse Biosciences!???? Pulse Biosciences, Inc., a key player in the MedTech industry, has recently appointed a new CEO. This strategic move is aimed at driving innovation, fostering growth, and shaping the future trajectory of the company in the dynamic healthcare landscape. The company's innovative technology, delivering nanosecond-duration pulses of electrical energy, shows promise in improving atrial fibrillation (AFib) treatments by enabling faster ablations through thicker tissue with potential safety advantages over existing surgical thermal technologies. Recently receiving 510(k) clearance for its Cellfx electrode system in March, Pulse is strategically positioning itself to tap into the surgical AFib market and larger catheter opportunities. The company's leadership team has been restructured to drive forward this plan, with a new CEO, Burke Barrett, taking the reins from Kevin Danahy, who now leads the pilot launch of the Cellfx percutaneous electrode system. Read more here: https://lnkd.in/eDp7Agha #PulseBiosciences #MedTechInnovation #AtrialFibrillation #HealthcareTechnology ????